drugset / Trial / NCT06679985
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Timeline
- Start
- 2024-12-20
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Casdozokitug | Monoclonal antibody | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Toripalimab | Monoclonal antibody | — | — |